Skip to main content
Log in

Durable complete remission after brentuximab vedotin in a patient with relapsed and refractory Hodgkin lymphoma (HL)

  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

We present a case of a 23-year-old female patient with relapsed classical Hodgkin lymphoma in reduced general condition. She was refractory after multiple lines of prior chemotherapy including autologous stem cell transplantation. By applying a targeted therapy concept using brentuximab vedotin (SGN-35), the patient experienced a rapid clinical improvement with loss of B symptoms immediately after the first treatment cycle. Elevated serum levels for C-reactive protein (CRP) and lactate dehydrogenase (LDH) returned to normal, and a significant improvement of hemoglobin levels were observed. Moreover, after administration of 16 cycles, the patient remains in complete remission, lasting now for > 15 months. Tolerability of treatment was excellent without evidence of infections or peripheral neuropathy. This case illustrates the clinical potential of brentuximab vedotin in patients with end-stage Hodgkin lymphoma who would otherwise have only limited treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Jona A, Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Blood Rev. 2010;24:233–8.

    Article  PubMed  Google Scholar 

  2. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates of the NCCN guidelines. J Natl Compr Cancer Net. 2012;10(5):589–97.

    Google Scholar 

  3. Eichenauer DA, Engert A, Dreyling M. Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi55–8.

    Google Scholar 

  4. Horning SJ, Fanale M, de Vos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort. Ann Oncol. 2008;20:Abstract 118.

  5. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21.

    Article  PubMed  CAS  Google Scholar 

  6. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:1–7.

    Article  Google Scholar 

  7. Smith SE, Chen R, Gopal AK, et al. Long-term follow-up results of an ongoing pivotal study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL). EHA, Abstract #1109, June 14–17 2012, Amsterdam.

  8. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30(7):631–7.

    Article  PubMed  CAS  Google Scholar 

  9. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res. 2011;17:6428–36.

    Article  PubMed  CAS  Google Scholar 

  10. Adcetris: EPAR, Product Information, October 2012. www.ema.europa.eu.

  11. Schwartz RS. Paul Ehrlich’s magic bullets. N Engl J Med. 2004;350:1079–80.

    Article  PubMed  CAS  Google Scholar 

  12. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Ann Rev Med. 2013;64:15–29.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that there is no actual or potential conflict of interest in relation to this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Johannes Drach MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drach, J., Huk, I. & Lamm, W. Durable complete remission after brentuximab vedotin in a patient with relapsed and refractory Hodgkin lymphoma (HL). memo 6, 119–122 (2013). https://doi.org/10.1007/s12254-013-0078-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-013-0078-8

Keywords

Navigation